Sadra Medical Journal

The Impact of 12-Week Aerobic Exercise on Serum Levels of Cardiotrophin-1 in Female Patients with Hypertension

Document Type : Original Article

Authors

Somayeh Abedzadeh 1
Farshad Ghazaliyan 2
Hosein Abed Natanzi 2
Hojatollah Nikbakht 3
Mandana Gholami 2

1 Ph.D.Student of Department of Sport Physiology, Scince and Research Branch, Isiamic Azad University, Tehran, Iran

2 Assistant Professor, Department of Physical Education and Sport Sciences, Scince and Research Branch, Isiamic Azad University, Tehran, Iran

3 Associate Professor, Department of Physical Education and Sport Sciences, Scince and Research Branch, Isiamic Azad University, Tehran, Iran

https://doi.org/10.30476/smsj.2023.90254.1224
Abstract
Introduction: Cardiotrophin-1 (CT-1) is an interleukin-6-related cytokine with known hypertrophic and protective actions upon cardiac myocytes. The present study aimed to investigate the impact of 1- week aerobic exercise on serum levels of cardiotrophin-1 in female patients with hypertension.
Methods: in this study, 35 old women aged 50 to 70 were randomly divided into two groups (15 controls and 15 controls). The exercise program included aerobic exercises conducted increasingly 3 times a week for 12 weeks. Before the exercise, and 24 hours after the last session, blood samples and the body composition were taken. Data were collected and analyzed using one-way ANCOVA and Tukey post hoc test at a significant level of P≤0/05.
Results: According to the results, twelve weeks of exercise did not significantly affect CT-1 level.
Conclusion: Overall, it seems that 12-week aerobic exercise has been beneficial in patients with hypertension and has been improving myocardial function; however, further studies are needed.

Keywords

Aerobic Exercise
Cardiotrophin-1
Hypertension
  1. World Health Organization [WHO]. (2013). A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013 (No. WHO/DCO/WHD/2013.2). World Health Organization. https://doi.org/10.1136/bmj.1.4815.882-a.
  2. Dennis H Lau, Stanley Nattel , Jonathan M Kalman , Prashanthan Sanders. Modifiable Risk Factors and Atrial Fibrillation. Review Circulation. 2017 Aug 8;136(6):583-596. doi: 10.1161/CIRCULATIONAHA.116.023163.
  3. Paul K Whelton, Robert M Carey, Wilbert S Aronow, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Review Hypertension. 2018 Jun;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066. Epub 2017 Nov 13.
  4. Zieman SJ, Melenovsky V, Kass DA. (2005). Mechanisms, pathophysiology, and therapy of arterial stiffness. Arteriosclerosis Thrombosis Vascular Biology 25 (5): 932–43.
  5. Lloyd-Sherlock, P., Beard, J., Minicuci, N., Ebrahim, S., & Chatterji, S. (2014). Hypertension among older adults in low-and middle-income countries: prevalence, awareness and control. International journal of epidemiology, 43(1), 116-128. https://doi.org/10.1093/ije/dyt215
  6. World Health Organization [WHO]. (2014). Global status report on noncommunicable diseases 2014. World Health Organization, p. 176.
  7. Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., Chen, J. and He, J. (2016). Global disparities of hypertension prevalence and control. Circulation, 134, 441–450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912.
  8. Wolz, M., Cutler, J., Roccella, E. J., Rohde, F., Thom, T., & Burt, V. (2000). Statement from the national high blood pressure education program: prevalence of hypertension.American Journal of Hypertension, 13(1), 103-104. https://doi.org/10.1016/S0895-7061(99)00241-1.
  9. Cutler, J. A., Sorlie, P. D., Wolz, M., Thom, T., Fields, L. E., & Roccella, E. J. (2008). Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension, 52(5),https://doi.org/10.1161/HYPERTENSIONAHA.108.113357
  10. Fryar, C. D., Ostchega, Y., Hales, C. M., Zhang, G., & Kruszon-Moran, D. (2017). Hypertension Prevalence and Control Among Adults: United States, 2015-2016. NCHS data brief, (289), 1-8.
  11. Giuseppe Schillacia,b, Giacomo Puccia,b, and Stefano Perlin. From hypertension to hypertrophy to heart failure:the role of cardiotrophin-1. Journal of Hypertension 2013, 31:474–476. DOI:10.1097/HJH.0b013e32835ed4bb.
  12. Pemberton CJ, Raudsepp SD, Yandle TG,Cameron VA, Richards AM. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res. 2005; 68: 109-17.
  13. Pan J, Fukuda M, Saito K, Matsuzaki J, Kodama H, Sano M. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res. 1999; 84: 1127-36.
  14. Fukuzawa J, Booz JG, Hunt RA, et al. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. Hypertension. 2003; 5: 1191-96.
  15. Lopez-Andres N, Inigo C, Gallego I, Dýez J,Fortuno M. Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. Endocrinol. 2008; 149: 4970-78.
  16. Funamoto M, Hishinuma S, Fujio Y, Matsuda Y, Kunisada K, Oh H. Isolation and characterization of the murine cardiotrophin-1 gene: expression and norepinephrine-induced transcriptional activation. J Mol Cell Cardiol.2000; 32: 1275-84.
  17. Janjua S, Lawrence KM, Ng LL, Latchman DS. The cardioprotective agent urocortin induces expression of CT-1. Cardiovasc Toxicol. 2003; 3: 255-62.
  18. Jiang ZS, Jeyaraman M, Wen GB, et al. Highbut not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1. J Mol Cell Cardiol. 2007; 42: 222-33.
  19. Liu J, Liu Z, Huang F, Xing Z, Wang H, Li Z. Pioglitazone inhibits hypertrophy induced by high glucose and insulin in cultured neonatal rat cardiomyocytes. Pharmazie. 2007; 62: 925-29.
  20. Hishinuma S, Funamoto M, Fujio Y, Kunisada K, Yamauchi- Takihara K. Hypoxic stress induces cardiotrophin-1 expression incardiac myocytes. Biochem Biophys Res Commun. 1999; 264: 436-40.
  21. Lopez B, Castellano J, MGonzalez A, Barba J, Dýez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension. 2007; 50: 977-83.
  22. Takuya Watanabe, Hanae Konii and Kengo Sato. Emerging Roles of Cardiotrophin-1 in the Pathogenesis and Biomarker of Atherosclerosis. www.mdpi.com/journal/jjournal. J 2018, 1, 94–105; doi:10.3390/j1010010.
  23. Gkaliagkousi, E.; Gavriilaki, E.; Chatzopoulou, F.; Anyfanti, P.; Triantafyllou, A.; Petidis, K.; Zamboulis, C.; Douma, S. Association between cardiotrophin 1 levels and central blood pressure in untreated patients with essential hypertension. Am. J. Hypertens. 2014, 27, 651–655.
  24. Song, K.; Wang, S.; Huang, B.; Luciano, A.; Srivastava, R.; Mani, A. Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: A meta-analysis. J. Clin. Hypertens. 2014, 16, 686–692.
  25. López, B.; González, A.; Querejeta, R.; Barba, J.; Díez, J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications. J. Hypertens. 2009, 27, 418–424.
  26. López, B.; González, A.; Querejeta, R.; Larman, M.; Rábago, G.; Díez, J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 2014, 63, 483–489.
  27. Amooali N, Daryanoosh F, Babaee Baigi MA, Mohamadi M. The Impact of 12 Weeks of Aerobic Exercise on SerumLevels of Cardiotrophin-1, Blood Pressure and Left Ventricular Hypertrophy in Hypertensive Elderly Women. Journal of Advances in Medical and Biomedical Research.2016,26.
  28. PAN Tong-bin,WANG Ya-yi,ZUO Wei,TANG Fang. (2012). The Changes of Cardiac Muscle Ultrastructure and Cardiotrophin-1 during Heavy Load Exercise and Recovery in Rats. Journal of Beijing Sport University,12.
  29. Luis Gamella-Pozuelo, BSc, Isabel Fuentes-Calvo, PhD, Manuel A. Go´mez-Marcos, MD, PhD,Jose´ I. Recio-Rodriguez, BSc, Cristina Agudo-Conde, BSc, Jose´ L. Ferna´ndez Martı´n, PhD,Jorge B. Cannata-Andı´a, MD, PhD, Jose´ M. Lo´pez-Novoa, PhD, Luis Garcı´a-Ortiz, MD, Phd and Carlos Martı´nez-Salgado, PhD(2015).Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk. Medicine _ Volume 94, Number 30, July 2015.
  30. Giuseppe Limongelli;Paolo Calabrò;Valeria Maddaloni;Antonio Russo;Daniele Masarone;Antonello D’Aponte;Teo Roselli;Rosa Bonauro;Raffaella D’Alessandro;Antonello D’Andrea;Giuseppe Pacileo;Francesco Limongelli;Raffaele Calabro(2010). Cardiotrophin-1 and TNF-α circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. Cytokine. Volume 50, Issue 3, June 2010, Pages 245-247. https://doi.org/10.1016/j.cyto.2009.12.007.

 

Sadra Medical Journal
Volume 10, Issue 3
July 2022
Pages 203-214

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us